OPTHEA LTD-SPON ADR (OPT) Stock Overview
NASDAQ:OPT - US68386J2087 - ADR
OPT Key Statistics, Chart & Performance
The current stock price of OPT is 3.41 USD. In the past month the price decreased by -34.55%. In the past year, price decreased by -1.16%.
OPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About OPT
Company Profile
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Company Info
OPTHEA LTD-SPON ADR
Suite 0403, Level 4, 650 Chapel Street, South Yarra
Melbourne VICTORIA 3141 AU
CEO: Megan Baldwin
Employees: 33
Phone: 61398260399
OPTHEA LTD-SPON ADR / OPT FAQ
What is the stock price of OPTHEA LTD-SPON ADR today?
The current stock price of OPT is 3.41 USD. The price increased by 7.23% in the last trading session.
What is the ticker symbol for OPTHEA LTD-SPON ADR stock?
The exchange symbol of OPTHEA LTD-SPON ADR is OPT and it is listed on the Nasdaq exchange.
On which exchange is OPT stock listed?
OPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OPTHEA LTD-SPON ADR stock?
10 analysts have analysed OPT and the average price target is 6.57 USD. This implies a price increase of 92.75% is expected in the next year compared to the current price of 3.41. Check the OPTHEA LTD-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OPTHEA LTD-SPON ADR worth?
OPTHEA LTD-SPON ADR (OPT) has a market capitalization of 524.75M USD. This makes OPT a Small Cap stock.
How many employees does OPTHEA LTD-SPON ADR have?
OPTHEA LTD-SPON ADR (OPT) currently has 33 employees.
What are the support and resistance levels for OPTHEA LTD-SPON ADR (OPT) stock?
OPTHEA LTD-SPON ADR (OPT) has a support level at 3.17 and a resistance level at 4.6. Check the full technical report for a detailed analysis of OPT support and resistance levels.
Is OPTHEA LTD-SPON ADR (OPT) expected to grow?
The Revenue of OPTHEA LTD-SPON ADR (OPT) is expected to decline by -37% in the next year. Check the estimates tab for more information on the OPT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OPTHEA LTD-SPON ADR (OPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OPT, evaluating the profitability, health, valuation and growth aspects
- OPTHEA LTD-SPON ADR (OPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OPTHEA LTD-SPON ADR (OPT) Sales and EPS estimates to see what analysts future expectations are.
- OPTHEA LTD-SPON ADR (OPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OPTHEA LTD-SPON ADR (OPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- OPTHEA LTD-SPON ADR (OPT) Stock Chart to make your own analysis
- OPTHEA LTD-SPON ADR (OPT) Latest news and press-releases to stay up to date.
Does OPTHEA LTD-SPON ADR (OPT) stock pay dividends?
OPT does not pay a dividend.
When does OPTHEA LTD-SPON ADR (OPT) report earnings?
OPTHEA LTD-SPON ADR (OPT) will report earnings on 2025-08-28, after the market close.
What is the Price/Earnings (PE) ratio of OPTHEA LTD-SPON ADR (OPT)?
OPTHEA LTD-SPON ADR (OPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
What is the Short Interest ratio of OPTHEA LTD-SPON ADR (OPT) stock?
The outstanding short interest for OPTHEA LTD-SPON ADR (OPT) is 0.36% of its float. Check the ownership tab for more information on the OPT short interest.
OPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OPT. When comparing the yearly performance of all stocks, OPT turns out to be only a medium performer in the overall market: it outperformed 59.46% of all stocks.
OPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPT. Both the profitability and financial health of OPT have multiple concerns.
OPT Financial Highlights
Over the last trailing twelve months OPT reported a non-GAAP Earnings per Share(EPS) of -2. The EPS increased by 16.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OPT Forecast & Estimates
10 analysts have analysed OPT and the average price target is 6.57 USD. This implies a price increase of 92.75% is expected in the next year compared to the current price of 3.41.
For the next year, analysts expect an EPS growth of 56.03% and a revenue growth -37% for OPT